Kiniksa (KNSA) files Form 144 for 20,000-share sale

Kiniksa Pharmaceuticals (KNSA) reports a Form 144 notice for the intended sale of 20,000 Class A ordinary shares on 04/06/2026, executed as a broker payment for a cashless exercise.

Rhea-AI Filing Summary

Kiniksa Pharmaceuticals (KNSA) reports a Form 144 notice for the intended sale of 20,000 Class A ordinary shares on 04/06/2026, executed as a broker payment for a cashless exercise. The filing also lists recent open-market dispositions by Barry D. Quart, including 12,528 shares on 02/03/2026 and 2,690 shares on 02/12/2026.

Insights

Corporate Governance Analyst

Form 144 records an insider sale tied to an option exercise and prior small open‑market disposals.

The filing shows an executed cashless exercise where a broker was used to satisfy option costs by delivering shares: 20,000 shares on 04/06/2026. Several prior small sales by Barry D. Quart are itemized with dates and gross proceeds.

These are routine Section 16 dispositions and do not by themselves indicate a change in corporate strategy; subsequent Form 4/5 or company disclosures would be needed for further context.

Key Figures

Shares to be sold: 20,000 shares Example prior sale: 12,528 shares Example prior sale proceeds: $567,136.00 +2 more

5 metrics

Shares to be sold 20,000 shares intended sale on 04/06/2026 via broker payment for cashless exercise

Example prior sale 12,528 shares sold on 02/03/2026 for $567,136.00 (Barry D. Quart)

Example prior sale proceeds $567,136.00 gross proceeds for 12,528 shares sold on 02/03/2026

Example prior sale 2,690 shares sold on 02/12/2026 for $121,050.00 (Barry D. Quart)

Example prior sale proceeds $121,050.00 gross proceeds for 2,690 shares sold on 02/12/2026

Key Terms

Form 144, cashless exercise, broker payment, Class A ordinary shares

4 terms

Form 144 regulatory

"Form 144 notice for the intended sale of 20,000 Class A ordinary shares"

Form 144 is a document that investors must file with the government when they plan to sell a large number of shares of a company's stock. It helps ensure transparency so everyone knows how many shares are being sold and when, which can impact the stock's price.

cashless exercise financial

"Broker Payment for Cashless Exercise"

A cashless exercise is a way for an option holder to convert stock options into actual shares without paying the purchase price in cash; instead they immediately give up a portion of the newly issued shares to cover the cost and any withholding taxes. Investors care because this process increases the number of shares available and can slightly dilute existing holdings, while also signaling how insiders or employees are realizing compensation without needing cash — similar to paying for a purchase by handing over part of what you just bought.

broker payment financial

"Broker Payment for Cashless Exercise executed on 04/06/2026"

Class A ordinary shares market

"Securities To Be Sold: Class A ordinary shares"

Class A ordinary shares are a type of ownership stake in a company that typically grants voting rights to shareholders, allowing them to have a say in important company decisions. They often come with priority in receiving dividends or profits, making them attractive to investors seeking influence and potential income. These shares help distinguish different levels of ownership and rights within a company's stock structure.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does KNSA's Form 144 report?

It reports an intended sale of 20,000 Class A ordinary shares. The sale was processed as a broker payment for a cashless option exercise on 04/06/2026, and the filing also lists several recent small dispositions by Barry D. Quart.

Who is the reporting party on this Form 144 for KNSA?

The filing identifies Barry D. Quart as a recent seller. Multiple prior sales by Quart are listed with dates and gross proceeds, indicating prior open‑market dispositions during February 2026.

Were the recent sales executed through a broker or as open‑market trades?

The 04/06/2026 transaction is listed as a broker payment for a cashless exercise. The prior February 2026 entries for Barry D. Quart appear as open‑market dispositions with listed share counts and gross proceeds.

Does the Form 144 show how much cash was raised from the listed sales?

Yes, individual sale proceeds are shown for each entry. Examples include $567,136.00 for 12,528 shares on 02/03/2026 and $121,050.00 for 2,690 shares on 02/12/2026.

Does this Form 144 change Kiniksa's outstanding share count or disclose dilution?

No change to outstanding shares or dilution is stated here. The filing documents specific share dispositions; it does not state any amendment to authorized shares or company‑level issuance in the provided excerpt.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/06/2026 - 04:55 PM Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001384243
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Kiniksa Pharmaceuticals International, plc
SEC File Number	001-38492
Address of Issuer	105 PICCADILLY, SECOND FLOOR LONDON UNITED KINGDOM W1J 7NJ
Phone	7814319100
Name of Person for Whose Account the Securities are To Be Sold	Quart Barry D
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Class A ordinary shares	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	20000	1000000.00	45900637	04/06/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Class A ordinary shares	04/06/2026	Employee Stock Option Exercise - see remarks	Kiniksa Pharmaceuticals, Ltd.			20000	04/06/2026	Broker Payment for Cashless Exercise

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/02/2026	830	37354.00
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/03/2026	12528	567136.00
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/04/2026	2602	117138.00
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/10/2026	110	4950.00
Barry D Quart 105 PICCADILLY, SECOND FLOOR LONDON X0 W1J 7NJ	Kiniksa Pharmaceuticals International, plc	02/12/2026	2690	121050.00

144: Remarks and Signature

Remarks	The shares on this filing may be sold over various dates.
Date of Notice	04/06/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	09/11/2025
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	Barry D Quart
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)